U.S. District Court for the District of New Jersey

Patent Litigation Profile: U.S. District Court for the District of New Jersey

Court Overview: The United States District Court for the District of New Jersey (D.N.J.) is a federal court within the Third Circuit, with courthouses in Newark, Trenton, and Camden. Historically a major venue for patent litigation, particularly for the pharmaceutical industry, the district has seen a significant resurgence in its patent docket. In 2024, the District of New Jersey became the fifth most popular patent venue in the U.S., experiencing a 77% year-over-year increase in patent case filings, with a total of 232 cases. This surge has positioned it ahead of the District of Delaware as the top venue for Abbreviated New Drug Application (ANDA) litigation.

Patent Docket Reputation: The District of New Jersey is a well-established forum for patent disputes, especially those involving pharmaceutical companies headquartered in the state. It is not considered a "rocket docket," and data on time-to-trial has been affected by the COVID-19 pandemic, which paused jury trials in 2020 and 2021. However, the court's experienced judiciary is a significant draw for litigants, who expect fair and reasonably prompt adjudication. The district's full complement of judges is seen as an advantage, ensuring cases receive necessary attention. Recent analyses suggest a trend of more favorable outcomes for patent holders in New Jersey compared to Delaware in the years leading up to 2024. In 2023, the patentee win rate in New Jersey reportedly rose to 21%, a high for the decade, compared to 3% in Delaware for the same period.

Local Rules and Procedures: The District of New Jersey operates under a comprehensive set of Local Patent Rules (L. Pat. R.), which are appended to the court's Local Civil Rules as Rule 9.3. First adopted in 2008 and modeled after the Northern District of California's rules, they are designed to streamline litigation by requiring early disclosure of infringement and invalidity contentions, crystallizing legal theories, and standardizing the claim construction (Markman hearing) process. The rules establish a structured schedule for the exchange of proposed claim terms, preliminary constructions, and the filing of a Joint Claim Construction and Prehearing Statement. Unlike some other districts, New Jersey's rules do not impose a limit on the number of claim terms that parties can propose for construction. Strict adherence is required, and failure to meet deadlines or show good cause for amending contentions can result in the loss of a claim or defense.

Notable Cases and Rulings: The court consistently handles high-stakes pharmaceutical patent litigation. Among the recently filed cases being tracked are ANDA actions typical of the district's docket, including Astellas US LLC et al. v. Dr. Reddys Laboratories Ltd and Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical (hainan) Co Ltd, both filed in April 2026. In another recent matter, Chief Judge Renée Marie Bumb granted a motion to stay a patent infringement litigation pending the outcome of USPTO ex parte reexamination proceedings for all 10 patents-in-suit, finding a stay appropriate given the early stage of the case and the USPTO's decision to reexamine all asserted patents.

Judges: The District of New Jersey is noted for its experienced bench and its deep expertise in managing complex patent cases, particularly ANDA litigation. The court is led by Chief Judge Renée Marie Bumb, who actively presides over patent cases. While many judges in the district handle patent matters, the concentration of pharmaceutical cases has led to a judiciary with a strong working knowledge of the specific demands of Hatch-Waxman litigation.